Significant Ownership of STEMPOINT CAPITAL LP
- Signature - Title
- /s/ Sean C. Tan - Sean C. Tan, Authorized Signatory
- Location
- New York, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by STEMPOINT CAPITAL LP.
Follow Filing Activity
Follow STEMPOINT CAPITAL LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of STEMPOINT CAPITAL LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | Common stock, par value $0.0001 per share | 8.4% | $3,979,818 | +$1,339,818 | 6,030,028 | +51% | StemPoint Capital LP | 31 Dec 2025 |
| SRZN | Surrozen, Inc. | Common Stock, $0.0001 par value per share | 7% | $12,798,168 | -$8,186,300 | 619,766 | -39% | StemPoint Capital LP | 31 Dec 2025 |
| VTGN | Vistagen Therapeutics, Inc. | Common Stock, par value $0.001 per share | 1.5% | $456,394 | -$1,266,690 | 616,749 | -74% | StemPoint Capital LP | 31 Dec 2025 |
Schedules 13D/G Reported by STEMPOINT CAPITAL LP:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.